SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-027332
Filing Date
2022-05-17
Accepted
2022-05-16 19:54:23
Documents
14
Period of Report
2022-05-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea160070-8k_allarity.htm   iXBRL 8-K 28359
2 PRESS RELEASE DATED MAY 16, 2022 ea160070ex99-1_allarity.htm EX-99.1 32400
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3894
  Complete submission text file 0001213900-22-027332.txt   253813

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE allr-20220516.xsd EX-101.SCH 2959
5 XBRL LABEL FILE allr-20220516_lab.xml EX-101.LAB 34916
6 XBRL PRESENTATION FILE allr-20220516_pre.xml EX-101.PRE 22789
8 EXTRACTED XBRL INSTANCE DOCUMENT ea160070-8k_allarity_htm.xml XML 3875
Mailing Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139
Business Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 22931792
SIC: 2834 Pharmaceutical Preparations